HbA1c, FPG, and total daily insulin doses decreased significantly after combination therapy with TZD and insulin in patients with type 2 diabetes mellitus, suggesting that the insulin-sensitizing characteristics of TZDs are likely more pronounced in patients who are not totally devoid of endogenous insulin secretion. The gene discussed is INS; the disease is type 2 diabetes mellitus.